Mr. Money Mustache

JUNE 21, 2022

Little did I know he was about to hit me with a case study request that struck home in so many ways that I knew we had to cover it right away. That sentence was just one piece of a sizable rant that this gentleman named Aaron contributed at the time, and I applauded him for sharing it.

Investing 52

Investing Financial Institutions Legal Stock Market 52

The Motley Fool

MAY 24, 2024

That same day, an Australian dairy worker also tested positive for avian flu, marking the first-ever human case of avian flu in that country. In a response to Barron's Magazine , Moderna confirmed that it was already in a Phase II study for an avian flu that's in the same family as the H5N1 strain.

Private Companies 246

Private Companies Returns Companies Investors 246

The Motley Fool

MARCH 26, 2024

The case for Eli Lilly Lilly's weight loss drug Zepbound is the main reason to consider buying the pharma stock. The case for Novo Nordisk The main draws for Novo Nordisk right now are its semaglutide products -- Ozempic for type 2 diabetes, Wegovy for weight loss and cardiovascular risk reduction, and Rybelsus for weight loss.

Prospects 187

Prospects Returns Investors Companies 187

The Motley Fool

MAY 12, 2024

In February, the biotech released data from several phase 3 studies for its next-gen CF therapy, vanza triple. The study pitted this newer product against Trikafta, which was itself a groundbreaking medicine capable of treating up to 90% of CF patients, approved in 2019. It started a rolling submission in the U.S.

Prospects 246

Prospects Returns Accounting Portfolios 246

The Motley Fool

APRIL 24, 2024

Two phase 3 studies of tirzepatide, the molecule in Zepbound, showed it reduced OSA severity by as much as 63% over the period of a year. The studies involved patients with moderate-to-severe OSA who were on positive airway pressure therapy as well as those who weren't. The studies met both primary and key secondary endpoints.

Returns 246

Returns Investors Portfolios Companies 246

The Motley Fool

MAY 22, 2024

NVAX data by YCharts The case for Novavax Novavax earned approval for its COVID-19 vaccine, Nuvaxovid, in various countries. Elsewhere, the biotech is racing toward the start of a phase 3 study for its combined COVID-19/flu vaccine, which it plans to kick off during the second half of the year. Let's take a look. In the U.S.,

Prospects 130

Prospects Stakes Capital Returns 130

The Motley Fool

MAY 26, 2024

Rivian is a perfect case study. If you had put $500 into Rivian stock the day it went public, how much would you have right now? The answer might surprise you. A $500 investment in Rivian would now be worth this much Investing in growth stocks can be tricky. Over the last 12 months, however, total sales were around $5 billion.

Investing 245

Investing Returns Portfolios Companies 245

The Motley Fool

MAY 5, 2024

Still, most of its programs haven't made it to phase 3 studies. The company's VGX-3100, a potential vaccine for cancer caused by human papillomavirus (HPV), looked promising at one point but ended up flopping in late-stage studies. If it fails this study, it could be pulled off the market. million recorded in 2022.

Prospects 130

Prospects Returns Investors Companies 130

The Motley Fool

MAY 21, 2024

In severe cases, NASH can lead to liver failure and death. Rezdiffra must prove effective in a confirmatory study to get final approval. Rezdiffra has so far shown effectiveness in multiple clinical trials, including a phase 3 study, although that doesn't guarantee success in the ongoing confirmatory study.

Returns 130

Returns Investors Portfolios Companies 130

The Motley Fool

JUNE 26, 2023

What a new study presupposes is. But, in this case, we're sure hoping it rhymes: According to the study, last decade's "deep learning" boom actually created a positive relationship between job growth and occupations with a high exposure to AI -- i.e., for high-skilled jobs, such as office jobs involving data work.

Banks 246

Banks Accounting Investing 246

The Motley Fool

FEBRUARY 3, 2024

This is especially the case when undocumented workers don't pay taxes. However, the nonprofit Center for Immigration Studies released a report in 2023 that argued legal migration could present problems for Social Security. The Center for Immigration Studies stated that legal immigrants who come to the U.S.

Legal 246

Legal Taxes Funds 246

The Motley Fool

MAY 26, 2024

There's no telling just how much money, but based on recent studies claiming that a 5% allocation is the ideal amount of exposure, we can begin to estimate the potential impact of institutional investors. Most notably, a recent ARK Invest study suggests that the ideal exposure level should be closer to 19%.

Hedge Funds 246

Hedge Funds Due Diligence Exchange-Traded Funds Pension Funds 246

The Motley Fool

MAY 9, 2024

I will provide key updates on our clinical programs, including an important interim data update on our TAMARACK Phase 2 study this afternoon. Our anticipated funding requirements reflect expected expenditures related to the ongoing Phase 2 TAMARACK and LORIKEET studies as well as our other ongoing clinical and preclinical studies.

Capital 130

Capital Investors Consultants Consulting 130

The Motley Fool

NOVEMBER 14, 2023

On Tuesday, Disney rolled out an economic impact study showing just how significant Disney World is to the Florida economy. Wallet Disney World The new study from Oxford Economics takes a look at Disney's total statewide impact for its fiscal 2022, which ended in September of that year, and concludes that the company had a $40.3

Education 246

Education Prospects Taxes Capital 246

The Motley Fool

APRIL 28, 2024

It recently delivered more positive results from late-stage studies. have OSA, the condition is dangerously underdiagnosed, with about 85% of cases being left untreated. Eli Lilly recently released positive results from two phase 3 studies for tirzepatide in patients with OSA and obesity.

Prospects 246

Prospects Returns Investors Portfolios 246

The Motley Fool

SEPTEMBER 16, 2023

6, per a small study published in the New England Journal of Medicine (NEJM), Ozempic might be tremendously helpful for patients with type 1 diabetes, too, potentially freeing them from the need to take insulin with their meals to control their blood sugar. As of Sept. So, let's unpack the latest good news. million people in the U.S.

Shareholders 242

Shareholders Investors Funds Companies 242

The Motley Fool

JULY 22, 2023

The bullish case for Travere is that it obtained accelerated approval for Filspari earlier this year to treat IgA nephropathy, a kidney condition also known as Berger's disease. Huge opportunities for a tiny biotech Keith Speights (Viking Therapeutics) : In many cases, a biotech with a market cap of only around $1.5

Companies 240

Companies Investors Returns Portfolios 240

The Motley Fool

APRIL 24, 2024

The case for Archer Aviation Archer Aviation, a trailblazer in the small-cap transportation space, is making significant strides in the development of an electric vertical take-off and landing (eVTOL) aircraft. The case for Ocular Therapeutix Ocular Therapeutix is a specialist in eye diseases.

Funds 244

Funds Returns Capital Companies 244

The Motley Fool

APRIL 16, 2024

Women have the edge A 2021 Fidelity study found that women outperform men in investment returns by 0.4%, and an old study from UC Berkeley found that gap was nearly 1%. Finally, we also approach market volatility with a calmer reaction -- Fidelity's study determined that 51% of us will wait out any market hiccups, vs. 43% of men.

Investors 130

Investors Exchange-Traded Funds Accounting Returns 130

The Motley Fool

FEBRUARY 23, 2024

With that in mind, Morgan Stanley analyst Benjamin Swinburne has set a bull-case price target of $125 per share on Roku (NASDAQ: ROKU). Similarly, Josh Baer at Morgan Stanley has set a bull-case price target of $115 per share on Docebo (NASDAQ: DCBO). The S&P 500 returned an average of 169% during past bull markets.

Returns 241

Returns Shareholders Investors Companies 241

The Motley Fool

APRIL 21, 2024

But that could be an unwarranted fear in this case. According to some studies, AI's long-term potential is enormous. Studies show that AI uses tremendous computing power, naturally stimulating demand for more data centers. Here is why Supermicro, as it is also known, could be a brilliant buy today. According to a U.S.

Returns 246

Returns Portfolios Investors Companies 246

The Motley Fool

MARCH 13, 2024

Bull case: The worst is over Keith Speights : I'll readily admit that a lot has gone wrong for Moderna over the last couple of years. All you need to do is take a glance at the vaccine maker's stock chart to know that's the case. In some cases, investors may be waiting for Moderna to deliver on some of its promises before diving in.

Prospects 130

Prospects Returns Investors Companies 130

The Motley Fool

MAY 2, 2024

In addition, along with our partner Merck, we expanded studies for individualized neoantigen therapy, INT, into three new indications. At Vaccines Day, we shared updates from core administration studies of RSV confirming the ability to administer our vaccine and other vaccines given during the respiratory season.

Consultants 130

Consultants Consulting Taxes Banks 130

The Motley Fool

MARCH 14, 2024

Food and Drug Administration (FDA) declined to grant accelerated approval to donanemab in January 2023 due to a lack of data from long-term, late-stage studies. If Eli Lilly had earned this nod, it still would have had to seek full approval after directly confirming efficacy in phase 3 studies. So this setback wasn't a big deal.

Investors 130

Investors Prospects Returns Stock Market 130

The Motley Fool

APRIL 1, 2024

Pfizer has 112 programs in its pipeline, including 31 in phase 3 studies. Some people, particularly those at significant risk of severe cases of the disease, continue to get inoculated. The biotech is running several phase 3 studies for other promising candidates, too. So, long-term investors shouldn't give up on the stock.

Buyout 245

Buyout Portfolios Returns Investors 245

The Motley Fool

AUGUST 21, 2023

COVID-19 cases and hospitalizations are back on the rise, thanks to new mutations, especially one nicknamed Eris. Meanwhile, the BioNTech-Pfizer partnership also announced last week its new vaccine aimed at the XBB subvariants was also effective against the Eris strain in a study performed on mice.

Companies 246

Companies Investors Returns Investing 246

The Motley Fool

SEPTEMBER 15, 2023

A study from Nationwide Agency Forward found that 44% of homeowners are delaying routine home maintenance tasks. The study also found that 31% of homeowners are delaying necessary repairs and renovations. It may seem like you have plenty of time to complete home maintenance and repair projects, but that may not be the case.

Financing 245

Financing Finance Banks Accounting 245

The Motley Fool

MAY 5, 2024

More than 40% of baby boomers expect their benefits to be their primary income source in retirement, according to a 2023 report from the Transamerica Center for Retirement Studies, so it's wise to make the most of them. If you're married, you may be entitled to extra money each month in the form of spousal benefits.

Portfolios 242

Portfolios Returns Investors Investing 242

The Motley Fool

JANUARY 22, 2024

That's not really been studied very much, nor has it been studied if there's ways to wean you off them. That isn't the case. But Leqembi, the newer drug, has, I think a stronger case to make. Those are going to be really interesting studies. One was that they had the results of their lung cancer study.

Companies 245

Companies Shareholders Investors Investing 245

The Motley Fool

MAY 9, 2024

The study demonstrated a statistically significant reduction in knee OA pain at 6 months as assessed by the Western Ontario McMaster University arthritis Index pain scale compared to the subjects treated with saline control. ReNu showed a favorable safety profile, which is consistent with our prior studies.

Securities and Exchange Commission (SEC) 130

Securities and Exchange Commission (SEC) Accounting Debt Amortization 130

The Motley Fool

MAY 16, 2024

Martin has built a career on studying start-ups and their founders. There's a really classic study that really spurred me onto a lot of this work I do with start-ups that surveyed a bunch of venture capitalists. The study revealed that 65% of start-ups failed because of people issues. It was, by far, the most important thing.

Venture Capital 130

Venture Capital Shareholders Companies Returns 130

The Motley Fool

MARCH 7, 2024

In this case, though, another product took center stage. During this event, the company reported results from a phase 1 study evaluating the experimental obesity drug amycretin. However, the results for amycretin were from an early-stage clinical study. after 12 weeks, according to a report by Reuters.

Returns 147

Returns Capital Investors Portfolios 147

The Motley Fool

MAY 16, 2024

A new Chromebook If your child is graduating high school and heading to college, they may need a laptop to aid in their studies. With that purchase, you get free tech support in case there are any issues and a free two-year warranty. But you may not want to invest in such an expensive one. A Chromebook generally fits the bill.

Investing 130

Investing Financing Finance 130

The Motley Fool

JUNE 17, 2023

Some of the use cases are really interesting to me, Nick, you have watching movies where it's going to basically be able to expand the screen to cinema size, videoconferencing, FaceTime where it's going to scan your face. Any of the use cases you want to focus in on? But that may not be the case.

Securities and Exchange Commission (SEC) 245

Securities and Exchange Commission (SEC) Stakes Assets Education 245

The Motley Fool

APRIL 8, 2024

Reasons to buy beaten-down Agenus stock These days, Agenus is a clinical-stage cancer drug developer without any approved products to sell, but this wasn't always the case. Botensilimab is in a larger phase 2 study with similar colon cancer patients and a control group for making comparisons.

Investment Banking 130

Investment Banking Investment Banks Shareholders Banks 130

The Motley Fool

MAY 6, 2024

Additionally, we are conducting the EMERGE study, a multicenter phase 3 single-group trial evaluating the efficacy and safety of AXS-07 in adults with a prior inadequate response to an oral CGRP inhibitor. This study is similar in design to the completed positive ACCORD-1 trial. Would you anticipate AXS-05 to become front line.

Securities and Exchange Commission (SEC) 130

Securities and Exchange Commission (SEC) Banks Companies Capital 130

The Motley Fool

APRIL 27, 2024

The main compound in each drug is called tirzepatide, and Lilly has been actively exploring additional use cases for the breakthrough medicine. Although it's still early, there are some indicators that GLP-1 agonists have much more potential beyond current use cases. According to the bank's research, the U.S. compared to 6.4%

Investors 130

Investors Banks Portfolios Returns 130